The MS neurologist at Cleveland Clinic’s Lou Ruvo Center for Brain Health discussed the impact that propensity score has had on real-world data analysis, the use of additional outcome measures in trials, and the increasing understanding of progressive disease.
Preclinical trials and success stories suggest that much is riding on vector-based therapies for the treatment of rare neurological conditions.
The head of neurology at the Sunnybrook Health Sciences Centre of the University of Toronto spoke about the limited available normative sleep data, and shared insight into the findings of the meta-analysis he and colleagues conducted of more than 150 studies.
A new analysis of NASR data suggests that the risk for sudden unexpected death in epilepsy exists across a broad range of epilepsies, including those patients who are seizure-free, have never had tonic-clonic seizures, or those diagnosed with a benign epilepsy syndrome.
The clinical assistant professor of neurology and neurosurgery at the University of Texas discussed the need to identify men who may be at risk for myasthenia gravis despite a lack of willingness to see their physician.
The neurology resident at the University of California San Francisco spoke about the role that seizure diaries can play in a patient’s peace of mind, as well as in the understanding of that patient’s response to a given treatment.
The entire 25-patient cohort from the NURTURE study was able to sit without support, while 88% were able to walk independently, according to new 45-month data in presymptomatic patients with spinal muscular atrophy.
What does compensation for neurologists look like these days? Would you choose neurology all over again?
PF-06939926 is a recombinant adenoassociated virus serotype 9 (AAV9) capsid carrying mini-dystrophin, a shortened version of the human dystrophin gene, under the control of a muscle-specific promoter.
After receiving a refusal to file letter and undergoing a Type A meeting with the FDA, Zogenix has announced that it plans to resubmit an NDA for fenfluramine (Fintepla) for the treatment of seizures associated with Dravet syndrome in Q3 of 2019.
The mean decrease from baseline in latency to persistent sleep was 15 minutes for placebo, 30 minutes for seltorexant 5 mg, 50 minutes for 10 mg, and 48 minutes for 20 mg.
VMAT2, given its role in presynaptic packaging, storage, and release of dopamine, has emerged as a promising target for therapeutic interventions to manage movement disorders.
Neurology News Network for the week ending June 29, 2019.
The clinical assistant professor of neurology and neurosurgery at the University of Texas spoke about the staggering number of men who forgo seeing physicians for serious conditions and how the clinical community can help address the challenge.
The director of the Sleep-Wake Disorders Center at Montefiore Medical Center spoke about one of the major symptoms of narcolepsy and how to identify it during diagnosis.
A lot of hype and hope surround this treatment class, making reasonable expectations difficult to form for practitioners and patients alike.
The FDA approval was based on data from the phase 3 PREVENT trial in which 98% of patients treated with eculizumab were relapse free.
Sleep apnea and other sleep disorders are increasingly being recognized as major factors in the etiology and treatment of a host of neurological diseases, but awareness in the neurology community still has room to grow.
